Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Clinical evidence

BOND-003 cohort P

58 evidence topics · 16 sources

Objective
Location and study date
Registry dates for the whole BOND-003 study
Study design
Eligibility criteria
Cohort P inclusion criteria

“Have ECOG performance status of 0 to 2.” (opens the source at this quote in a new tab)

“Have pathologically confirmed (WHO grading system employed for tumor grading) (Compérat 2019) BCG-unresponsive HG Ta/T1 papillary disease without CIS.” (opens the source at this quote in a new tab)

“Pathologically confirmed recurrent HG Ta/T1 papillary disease without CIS within 6 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).” (opens the source at this quote in a new tab)

“Patients with HG Ta: Completion of qualifying BCG treatment (e.g., "5+2" minimum exposure) within 12 months of the initial qualifying dose of BCG” (opens the source at this quote in a new tab)

“Patients with HG T1: Patients may be eligible after the initial induction alone (5 of 6 doses of an induction course) as the qualifying BCG treatment.” (opens the source at this quote in a new tab)

“Completion (last dose) of qualifying BCG treatment within 12 months of study enrollment.” (opens the source at this quote in a new tab)

“Pathological confirmation of BCG-unresponsive HG Ta/T1 papillary disease without CIS within 14 days of study enrollment.” (opens the source at this quote in a new tab)

“Have all Ta and/or T1 disease resected, prior to study treatment (e.g., prior to Day 1 treatment).” (opens the source at this quote in a new tab)

“Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using high-grade event-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Efficacy population stated in the November 2026 investor presentation
FieldCretostimogene, BOND-003 Cohort P
Efficacy population“N=54”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and disease characteristics of the safety dataset
Characteristicn%
Male“44”“78.6”
Female“12”“21.4”
Age, mean (SD), years“71.6 (9.3)”
Age, median (range), years“74.0 (45-87)”
Age < 65 years“13”“23.2”
Age ≥ 65 and < 75 years“18”“32.1”
Age ≥ 75 years“25”“44.6”
ECOG PS 0“48”“85.7”
ECOG PS 1“8”“14.3”
HG Ta at study entry“33”“58.9”
HG T1 at study entry“23”“41.1”
Prior BCG instillations, median (range)“9.0 (5 – 21)”
Tumor stage at study entry as stated in November 2026
Characteristicn%
HG Ta at study entry“37”“66.1”
HG T1 at study entry“19”“33.9”
Efficacy results
High-grade event-free survival by tumor stage
Twelve-month and 24-month estimates as of November 2026
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse events reported in more than 10% of participants
Preferred termAny grade, n (%)Grade ≥ 3, n (%)
Participants with ≥1 TRAE“40 (71.4%)”“0 (0)”
Bladder spasm“26 (46.4%)”“0 (0)”
Dysuria“22 (39.3%)”“0 (0)”
Pollakiuria“14 (25.0%)”“0 (0)”
Urgency“11 (19.6%)”“0 (0)”
Study limitations
Summary: limitations of the Cohort P evidence
  • Design: Cohort P is a single-arm, open-label cohort with no concurrent control. FDA guidance recommends a randomized, controlled design with a time-to-event endpoint for disease resected at or before trial entry and states that “Time-to-event endpoints are uninterpretable in a single-arm trial”.
  • Maturity: all reported efficacy results come from one data cutoff (September 1, 2025), at a median follow-up of 6.0 months. Of 56 participants in the safety dataset, 51 were efficacy evaluable, and 5 censored participants were pending efficacy assessment. Twelve-month estimates were “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
  • Publication status: the results have been reported in congress presentations, company filings, and press releases. No peer-reviewed publication of Cohort P was identified.
  • Primary endpoint wording: the registry states a high-grade event-free survival endpoint (“all-cause High Grade Event Free Survival (HG-EFS)”), while one passage of the Form 10-K states that the primary endpoint “is overall event-free survival” and another passage of the same filing states that it “is HG-EFS”. The SUO 2025 slide labels the same three Kaplan-Meier estimates HG-RFS.
  • Sample size: the registry target is 75 participants, while 56 participants were in the safety dataset at the data cutoff, and a 2025 trial-in-progress poster reported “Completed Enrollment”. The registry still lists Cohort P as open to enrollment. The 2026 investor presentation gives an efficacy population of “N=54”, against 51 efficacy-evaluable participants in the congress presentations.
  • Inconsistent figures for the same data cutoff: the SUO 2025 podium reports 33 HG Ta (58.9%) and 23 HG T1 (41.1%) participants and one 2026 poster reports 8 re-induced participants; another 2026 poster reports 37 HG Ta (66.1%) and 19 HG T1 (33.9%) participants and 11 re-induced participants. The Form 10-K lists hematuria among the most common TRAEs, which the SUO 2025 table of TRAEs does not include.
  • Regulatory role: company documents describe the cohort as “Phase 3”, as “an exploratory study”, and as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the BLA would be broadened to include high-grade papillary-only disease.
  • Generalizability: 96.4% of participants were enrolled in the US, 87.5% were White, and 85.7% had ECOG performance status 0. No health-related quality of life or patient-reported outcome results were identified.
  • Comparisons: sponsor materials set Cohort P estimates beside results of other agents from separate trials; the investor presentation states that these data are not based on head-to-head or comparator studies.